Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Higher-dose rifampicin dose-ranging trial in pulmonary tuberculosis
PACTR201104000281203Suspended
- Sponsor
- Radboud University Medical Center
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of rifampicin in Tuberculosis (TB) and pulmonary tuberculosis (TB) (6 arms), sponsored by Radboud University Medical Center. Primary endpoints: Safety, Tolerability and 2 more. Started May 2011; status: suspended.
02
Drugs
rifampicin
03
Conditions
Tuberculosis (TB)pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on PACTR201104000281203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201104000281203.